GleamWall
中文EN

EMMA Emmaus Life Sciences, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 822370 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.1%
TTM net income YoY-19.2%
TTM EPS YoY-8.3%
Revenue 3-yr CAGR-21.0%
Net income 3-yr CAGR—

Margins

Gross margin92.1%
Operating margin24.8%
Net margin-61.9%
FCF margin—
EBITDA margin25.2%

Returns

ROE—
ROA-45.1%
ROIC (approx.)—
Asset turnover0.73x

Leverage & solvency

Liabilities / assets487.1%
Debt / equity—
Current ratio0.06x
Interest coverage0.44x

Cash quality & payout

Operating cash flow / net income-0.22x
Accruals ratio-54.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.89M$6.32M$1.98M$3.85M$3.38M$2.82M$2.41M$3.29M
Cost of revenue$369,000$344,000$168,000$235,000$247,000$150,000$225,000$309,000
Gross profit$1.52M$5.97M$1.81M$3.62M$3.13M$2.67M$2.18M$2.98M
R&D expense$58,000$116,000$40,000$31,000$50,000$56,000$176,000$137,000
SG&A expense$1.48M$1.57M$1.85M$1.80M$1.73M$2.31M$2.34M$2.29M
Operating income-$369,000$3.79M-$823,000$886,000$695,000-$370,000-$980,000-$557,000
Interest expense$1.86M$1.60M$2.13M$2.27M$1.93M$1.68M$1.26M$1.28M
Pretax income-$4.74M$1.34M-$3.33M-$1.94M-$1.50M-$1.73M-$2.33M-$1.74M
Income tax$4,000-$1,000$4,000$16,000$579,000-$590,000$4,000$6,000
Net income-$4.74M$1.34M-$3.33M-$1.95M-$2.08M-$1.14M-$2.33M-$1.75M
EBITDA-$355,000$3.81M-$808,000$901,000$710,000-$366,000-$975,000-$552,000
EPS (basic)-0.070.02-0.05—-0.03-0.02-0.04—
EPS (diluted)-0.070.02-0.05—-0.03-0.02-0.04—
Weighted avg. shares (diluted)70.19M120.54M70.19M—63.87M63.87M63.87M—
Balance sheet
Cash & equivalents$971,000$2.81M$1.07M$2.13M$293,000$886,000$1.33M$1.39M
Receivables$1.52M$709,000$2.05M$2.80M$2.62M$2.07M$2.06M$2.62M
Inventory$1.42M$1.59M$1.91M$1.55M$1.21M$1.31M$1.44M$1.64M
Current assets$4.68M$6.00M$6.00M$7.75M$4.79M$5.01M$5.65M$6.77M
PP&E, net$73,000$86,000$98,000$113,000$128,000$143,000$41,000$46,000
Total assets$17.73M$16.37M$18.70M$21.44M$20.76M$23.34M$22.48M$23.60M
Current liabilities$72.89M$66.12M$70.54M$69.07M$64.17M$62.08M$64.92M$63.55M
Long-term debt$25.02M$24.99M$26.56M$27.13M$29.07M$29.73M$29.01M$28.96M
Total debt$25.02M$24.99M$26.56M$27.13M$29.07M$29.73M$29.01M$28.96M
Total liabilities$86.39M$82.55M$86.56M$85.04M$80.24M$79.05M$81.08M$80.08M
Shareholders' equity-$68.65M-$66.18M-$67.86M-$63.61M-$59.49M-$55.70M-$58.60M-$56.48M
Net debt$24.05M$22.18M$25.49M$25.00M$28.78M$28.85M$27.67M$27.58M
Shares outstanding70.19M70.19M70.19M70.19M63.87M63.87M63.87M63.87M
Cash flow statement
Operating cash flow-$1.67M$1.69M-$344,000$2.21M$409,000-$2.91M$279,000$343,000
Capital expenditure$0——$0$0——$6,000
Free cash flow-$1.67M——$2.21M$409,000——$337,000
Investing cash flow-$15,000$1.58M$0$0$0$2.17M$0-$2,000
Financing cash flow-$168,000-$1.53M-$702,000-$362,000-$1.00M$284,000-$345,000-$195,000
Depreciation & amortization$14,000$14,000$15,000$15,000$15,000$4,000$5,000$5,000
Stock-based compensation$0$0$1,000$7,000$9,000-$1,000$10,000$29,000

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.